米泊美生钠(Mipomersen sodium) - 药物靶点：APOB_专利_临床

概要

基本信息

药物类型

ASO

别名

Mipomersen、Mipomersen sodium (USAN)、ISIS-301012

+ [1]

靶点

APOB

作用机制

APOB抑制剂(载脂蛋白B-100抑制剂)

治疗领域

遗传病与畸形内分泌与代谢疾病心血管疾病+ [1]

在研适应症-

非在研适应症

先天性畸形冠心病冠状动脉疾病+ [8]

原研机构

Ionis

在研机构-

非在研机构

Kastle Therapeutics LLC初创企业

Ionis Pharmaceuticals, Inc.

Genzyme Corp.

最高研发阶段撤市

首次获批日期

美国 (2013-01-29),

II a型高脂蛋白血症

最高研发阶段(中国)-

特殊审评孤儿药 (美国)、临床急需境外新药 (中国)

登录后查看时间轴

结构/序列

Sequence Code 31118438

来源: *****

关联

21

项与米泊美生钠相关的临床试验

CTRI/2012/09/003013

/ Active, not recruiting临床3期

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol - FOCUS FH

开始日期2012-09-01

申办/合作机构

Genzyme Ltd

NCT01598948

/ Completed临床3期IIT

Effect of Mipomersen on LDL-Cholesterol Levels in Patients With Severe LDL-Hypercholesterolemia and Atherosclerosis Treated by Regular LDL-Apheresis

Elevated LDL-cholesterol is a major risk factor for heart disease. In patients with heart disease LDL-cholesterol should be lowered to levels below 70 mg/dl to prevent progression of disease. In most patients life style modification together with lipid lowering drug therapy is sufficient to achieve this goal. In some patients with severe forms of hypercholesterolemia, this may not be sufficient to reach goals and regular lipid apheresis (a costly and time intensive form of therapy) may be performed. Mipomersen is a new drug (apoB antisense oligonucleotide) that can lower LDL-cholesterol even in the most severe forms of LDL-hypercholesterolemia by 25-47%. It is unknown whether and to what extent mipomersen can decrease LDL-cholesterol in patients treated with regular apheresis. Phase 1 of the study will test how 6 months of weekly therapy with mipomersen affects LDL-cholesterol in patients with severe LDL-hypercholesterolemia treated with regular apheresis. Phase 2 will test in how many patients this will result in a meaningful reduction of apheresis time, apheresis frequency or if apheresis can be stopped completely.

开始日期2012-08-01

申办/合作机构

Ludwig-Maximilians-Universität München

EUCTR2011-002539-24-DE

/ Not yet recruiting临床2期IIT

Effect of Mipomersen on LDL-Cholesterol Levels in Patients with Severe LDL-Hypercholesterolemia and Atherosclerosis Treated by Regular LDL-Apheresis - MICA

开始日期2012-05-03

申办/合作机构-

100 项与米泊美生钠相关的临床结果

登录后查看更多信息

100 项与米泊美生钠相关的转化医学

登录后查看更多信息

100 项与米泊美生钠相关的专利（医药）

登录后查看更多信息

167

项与米泊美生钠相关的文献（医药）

2024-03-01·Indian heart journal

Traditional and novel non-statin lipid-lowering drugs

Review

作者: Jain, Peeyush

Non-statin drugs find utility in the management of dyslipidaemia in mixed dyslipidaemia, patients with statin intolerance, and when guidelines directed low-density lipoprotein cholesterol (LDL-C) target cannot be achieved despite maximally tolerated statin. The most definite indication of fenofibrate monotherapy is fasting serum triglyceride >500 mg/dl to reduce the risk of acute pancreatitis It offers a modest reduction in cardiovascular events. The statin-ezetimibe combination is commonly used for lipid lowering particularly after ACS. Fish oils reduce serum triglycerides by about 25 %. EPA (and not DHA) seems to have cardioprotective effects. Despite cardiovascular outcome benefits, bile-exchange resins have limited use due to poor tolerance. Bempedoic acid added to maximally tolerated statin therapy is approved to lower LDL-C in adults with primary hypercholesterolemia or mixed dyslipidaemias, HeFH, in patients with ASCVD who require additional lowering of LDL-C, and in patients who are statin-intolerant. Inclisiran is a long-acting double-stranded small interfering RNA (siRNA) that inhibits the transcription of PCSK-9 leading to a decrease in PCSK9 generation in hepatocytes and an increase in LDL receptor expression in the liver cell membrane leading to about 50 % reduction in serum LDL-C levels. Lomitapide lowers plasma levels of all ApoB-containing lipoproteins, including VLDL, LDL, and chylomicrons by inhibiting the enzyme microsomal triglyceride transfer protein (MTP) and approved for the treatment of adult patients with homozygous familial hypercholesterolemia (HoFH). Close monitoring for hepatotoxicity is required. Mipomersen is a single-stranded synthetic antisense oligonucleotide (ASO) that affects the production and secretion of apoB-containing lipoproteins with demonstrated efficacy in both homozygous and heterozygous FH patients. It is approved for restricted use due to risk of hepatotoxicity. Pelacarsen is an antisense oligonucleotide that reduces the production of apo(a) in the liver.

2022-09-01·Bioanalysis

Development and multicenter validation of an LC–MS-based bioanalytical method for antisense therapeutics

Article

作者: Kato, Noriko ; Inoue, Takao ; Kakehi, Masaaki ; Saito, Yoshiro ; Matsunuma, Takayuki ; Sun, Yuchen ; Goda, Ryoya ; Hosogai, Ryuta ; Yamada, Masaki ; Takahara, Kentaro ; Okuzono, Takeshi ; Shimizu, Hisao ; Yamaguchi, Takeru ; Murata, Kazuyuki ; Kawabata, Mitsuhiko ; Yamane, Shinichi ; Nitta, Shin-ichiro ; Nakai, Keiko ; Yoshida, Tokuyuki ; Saito, Kosuke ; Fujita, Hisashi

Background: Many bioanalytical methods for antisense oligonucleotides (ASOs) using LC–MS have been reported. However, no data have been available on the reproducibility and robustness of a single bioanalytical method for ASOs. As such, in the current study, we evaluated the reproducibility and robustness of LC–MS-based bioanalytical methods for ASOs in multiple laboratories. Methods/Results: Seven independent laboratories were included in this study. Mipomersen was measured by ion-pairing LC–MS (IP-LC–MS) as a model ASO using different LC–MS. The validation results of calibration curve, accuracy, precision and selectivity met the criteria of conventional bioanalytical method validation guidelines using LC/GC–MS for drugs in all laboratories. Meanwhile, carryover (>20%) was detected in three laboratories. Conclusion: We first demonstrated the multicenter-validated IP-LC–MS bioanalytical method for ASOs. Our data showed that the method was sensitive, robust and reproducible. However, the occurrence of carryover should be carefully monitored in its future application.

2022-06-01·Drug metabolism and disposition: the biological fate of chemicals

Absorption, Distribution, Metabolism, and Excretion of US Food and Drug Administration–Approved Antisense Oligonucleotide Drugs

Review

作者: Rasmussen, Theodore P ; Gogate, Anagha ; Liu, Sunna ; Bahal, Raman ; Liu, Anna ; Zhong, Xiao-Bo ; Migliorati, Julia M ; Nair, Sreenidhi ; Manautou, José E

Absorption, distribution, metabolism, and excretion (ADME) are the key biologic processes for determination of a drug's pharmacokinetic parameters, which have direct impacts on efficacy and adverse drug reactions (ADRs). The chemical structures, dosage forms, and sites and routes of administration are the principal determinants of ADME profiles and consequent impacts on their efficacy and ADRs. Newly developed large molecule biologic antisense oligonucleotide (ASO) drugs have completely unique ADME that is not fully defined. ASO-based drugs are single-stranded synthetic antisense nucleic acids with diverse modes of drug actions from induction of mRNA degradation, exon skipping and restoration, and interactions with proteins. ASO drugs have a great potential to treat certain human diseases that have remained untreatable with small molecule-based drugs. The ADME of ASO drugs contributes to their unique set of ADRs and toxicity. In this review, to better understand their ADME, the 10 US Food and Drug Administration (FDA)-approved ASO drugs were selected: fomivirsen, pegaptanib, mipomersen, nusinersen, inotersen, defibrotide, eteplirsen, golodirsen, viltolarsen, and casimersen. A meta-analysis was conducted on their formulation, dosage, sites of administration, local and systematic distribution, metabolism, degradation, and excretion. Membrane permeabilization through endocytosis and nucleolytic degradation by endonucleases and exonucleases are major ADME features of the ASO drugs that differ from small-molecule drugs. The information summarized here provides comprehensive ADME characteristics of FDA-approved ASO drugs, leading to a better understanding of their therapeutic efficacy and their potential ADRs and toxicity. Numerous knowledge gaps, particularly on cellular uptake and subcellular trafficking and distribution, are identified, and future perspectives and directions are discussed. SIGNIFICANCE STATEMENT: Through a systematic analysis of the existing information of absorption, distribution, metabolism, and excretion (ADME) parameters for 10 US Food and Drug Administration (FDA)-approved antisense oligonucleotide (ASO) drugs, this review provides an overall view of the unique ADME characteristics of ASO drugs, which are distinct from small chemical drug ADME. This knowledge is useful for discovery and development of new ASO drugs as well as clinical use of current FDA-approved ASO drugs.

34

项与米泊美生钠相关的新闻（医药）

2024-12-13

·CPHI制药在线

国产降脂新药突破：恒瑞SHR-1918 III期临床正式启动

关注并星标CPHI制药在线近日，恒瑞医药自主研发的降脂新药SHR-1918首次启动了III期临床试验，标志着这一创新药物在研发进程中迈出了关键一步。SHR-1918是一款针对血管生成素样蛋白3（ANGPTL3）的单克隆抗体，旨在通过抑制ANGPTL3的活性，有效降低血清中的甘油三酯（TG）和低密度脂蛋白胆固醇（LDL-C）水平，为高脂血症患者提供新的治疗选择。 ANGPTL3单抗研发现状血管生成素样蛋白3（ANGPTL3）作为调节血脂代谢的重要因子，近年来在降脂药物研发中备受关注。ANGPTL3主要通过抑制脂蛋白脂肪酶（LPL）和内皮脂肪酶（EL）的活性，影响甘油三酯（TG）和低密度脂蛋白胆固醇（LDL-C）的代谢，从而与动脉粥样硬化性心血管疾病的发生发展密切相关。因此，针对ANGPTL3的单克隆抗体药物研发成为降脂领域的一大热点。目前，全球在研的ANGPTL3单抗仅有四款，其中再生元的依维苏单抗（Evinacumab）在2021年获得美国FDA批准，成为全球首个针对ANGPTL3功能的治疗药物，用于纯合子型家族性高胆固醇血症（HoFH）的治疗。然而，该药物尚未在中国上市，国内患者仍面临治疗选择有限的困境。恒瑞医药在多年持续研发投入的基础上，围绕ANGPTL3靶点进行了深入研究。SHR-1918不仅能够有效抑制ANGPTL3的活性，降低血清中的TG和LDL-C水平，还具有良好的安全性和耐受性。与此同时，国内外众多制药企业也在积极布局ANGPTL3单抗药物的研发。然而，由于ANGPTL3靶点的复杂性和药物研发的高风险性，目前仅有少数几款药物进入临床试验阶段。恒瑞医药的SHR-1918作为国内首个进入III期临床的ANGPTL3单抗药物，不仅在国内市场上占据领先地位，也在全球降脂药物研发领域崭露头角。恒瑞SHR-1918作用机制和特点恒瑞SHR-1918作为一种全人源抗ANGPTL3单克隆抗体（IgG4亚型），其作用机制独特且效果显著。SHR-1918能够与ANGPTL3的氨基端结构结合，阻断ANGPTL3与脂蛋白脂肪酶（LPL）和内皮脂肪酶（EL）的相互作用，从而恢复LPL和EL的活性，达到降低循环中的甘油三酯（TG）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）及高密度脂蛋白胆固醇（HDL-C）的作用。SHR-1918特点主要体现在以下几个方面：首先，SHR-1918具有显著的降脂效果。临床前动物模型研究表明，SHR-1918在降低LDL-C和TG水平方面表现出强大的疗效，且降脂效果具有剂量依赖性。在健康受试者中的I期临床试验结果也显示，SHR-1918单次皮下注射后能够有效持久降低LDL-C和TG水平，且未出现严重不良事件。此外，SHR-1918还具有独特的给药方式和方便的剂型。SHR-1918采用皮下注射的给药方式，避免了口服药物可能带来的胃肠道不适和肝脏首过效应等问题。同时，SHR-1918的剂型为注射液，规格为0.15g/支，方便患者使用和携带。SHR-1918在研发过程中还展现出了与其他降脂药物的协同作用潜力。临床前研究表明，SHR-1918与他汀类药物等常用降脂药物联合使用时，能够进一步增强降脂效果。恒瑞SHR-1918 I期临床数据在 2024 欧洲心血管学会（ESC）年会上，SHR-1918 的 I 期临床研究结果令人瞩目。SHR-1918 在健康受试者中显示出了良好的耐受性和药代动力学特性。安全性方面，在 100 至 1200mg 剂量范围内，SHR-1918 表现出良好的耐受性，未出现严重不良事件或导致治疗中断的不良事件。这为后续的临床研究和应用提供了坚实的安全保障。药代动力学特性上，SHR-1918 皮下注射给药后，随着剂量的增加，血清中的药物浓度相应上升，具有缓慢吸收和消除的特性。药物达峰时间在 8.0 至 10.0 天内，药物半衰期时间在 29.4 至 53.5 天。这样的特性使得药物在体内能够持续发挥作用，为降低血脂水平提供了稳定的药物浓度。疗效方面，与安慰剂相比，SHR-1918 在降低血清 LDL-C 和 TG 水平方面表现出显著效果，并具有剂量依赖性。300mg 及以上剂量水平的 LDL-C 降低超过 30%，持续 64 天以上，最高达 49.1%；TG 降低超过 50%，持续 85 天以上，最高达 82.8%。恒瑞SHR-1918价值和意义恒瑞 SHR-1918 III 期临床正式启动，这是一项意义重大的研究。该研究为多中心、随机、双盲、安慰剂对照，旨在评估对纯合家族性高胆固醇血症患者的 LDL-C 的降低作用。此项研究设计严谨，通过对大量患者的随机分组，确保了结果的可靠性和科学性。主要终点明确，即关注第 12 周患者的 LDL-C 水平相比于基线的百分比变化。纯合家族性高胆固醇血症是一种罕见且严重的遗传性疾病，患者由于低密度脂蛋白胆固醇受体的缺陷或缺失，导致 LDL-C 在血液中积累，增加心脏病和卒中的风险。目前可用的治疗选择虽然有多种，包括他汀类药物、依折麦布、洛美他派、米泊美生、PCSK9 单抗和 evinacumab 等，但许多患者仍难以达到理想的血脂控制水平。恒瑞 SHR-1918 的 III 期临床研究，为这些患者带来了新的希望。作为中国首个且唯一进入 III 期临床的 ANGPTL3 靶向药物，SHR-1918 有望在降脂领域取得重大突破。其通过抑制 ANGPTL3 的活性，降低血清中的甘油三酯和 LDL-C 水平，在前期的研究中已经展现出了良好的耐受性和药代动力学特性，以及显著的降脂效果。结语相信随着 III 期临床研究的深入开展，SHR-1918 将为高脂血症患者提供更有效的治疗手段，为我国降脂药物研发带来新的突破，也可能对整个降脂药物市场的格局产生重要影响。参考文献 1、恒瑞医药官方网站 END 【智药研习社近期直播】来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com ▼更多制药资讯，请关注CPHI制药在线▼ 点击阅读原文，进入智药研习社~

临床3期临床2期临床结果临床1期申请上市

2024-12-11

·echemi

Heng Rui Pharma Launches Phase III Trial for ANGPTL3 Monoclonal Antibody

According to information from the U.S. clinical trial registry Clinicaltrials on December 10, Chinese company Heng Rui Pharma has launched its first Phase III clinical trial (SHR-1918-301) for the ANGPTL3 monoclonal antibody SHR-1918. This drug marks the first domestic ANGPTL3 monoclonal antibody to enter the Phase III clinical trial stage. SHR-1918 is an ANGPTL3 monoclonal antibody developed by Heng Rui Pharma, which works by inhibiting ANGPTL3 activity to lower triglycerides (TG) and low-density lipoprotein cholesterol (LDL-C) levels in serum. LDL-C and TG are significant risk factors for the development of atherosclerotic cardiovascular diseases. ANGPTL3 plays a key role in lipid metabolism regulation by inhibiting lipoprotein lipase and endothelial lipase, thereby reducing the clearance of TG and LDL-C. In September this year, Heng Rui Pharma announced the results of its first Phase I study (SHR-1918-101) at the European Society of Cardiology (ESC) annual meeting. The study showed that SHR-1918 (100-1200mg, subcutaneously) demonstrated good tolerance and pharmacokinetic characteristics in healthy subjects, with a peak time of 8.0-10.0 days and a half-life of 29.4-53.5 days. Additionally, SHR-1918 effectively and durably reduced LDL-C and TG levels: patients receiving doses of SHR-1918 of 300mg or higher had LDL-C levels reduced by over 30% (up to 49.1%), lasting more than 64 days; TG levels were reduced by over 50% (up to 82.8%), lasting more than 85 days. Given the potential of SHR-1918 for treating rare dyslipidemia disorders, the drug received breakthrough therapy designation for homozygous familial hypercholesterolemia (HoFH) from the Chinese National Medical Products Administration (NMPA) in September. The launched Phase III study is a multicenter, randomized, double-blind, placebo-controlled clinical trial (n=45), aimed at evaluating the efficacy and safety of SHR-1918 in treating homozygous familial hypercholesterolemia (HoFH). The primary endpoint is the percentage change in LDL-C levels from baseline at week 12. Homozygous familial hypercholesterolemia (HoFH) is a rare and severe genetic disorder where patients accumulate LDL-C in the blood due to defects or deficiencies in low-density lipoprotein receptors (LDLR), increasing the risk of heart disease and stroke. Currently, available treatment options for these patients include statins (simvastatin, atorvastatin, and rosuvastatin), ezetimibe, lomitapide, mipomersen, PCSK9 monoclonal antibodies (evolocumab and alirocumab), and evinacumab. Among these, evinacumab (Regeneron/Ultragenyx) is the only marketed ANGPTL3 monoclonal antibody, with global sales of $80.9 million in 2023.

临床3期临床结果临床1期突破性疗法临床2期

2024-12-10

·医药魔方Info

恒瑞医药降血脂新药进入III期阶段

12月10日，美国临床试验收录网站Clinicaltrials显示，恒瑞医药启动了血管生成素样蛋白3（ANGPTL3）单抗SHR-1918的首个III期研究（SHR-1918-301）。该药物是首款进入III期阶段的国产ANGPTL3单抗。详情请点击阅读原文 SHR-1918是恒瑞医药自主研发的一款ANGPTL3单抗，通过抑制ANGPTL3的活性来降低血清中的甘油三酯（TG）水平和低密度脂蛋白胆固醇（LDL-C）水平。LDL-C和TG是动脉粥样硬化性心血管疾病发生发展的重要风险因素。ANGPTL3在调节脂质代谢中扮演着重要角色，能够通过抑制脂蛋白酶和内皮脂肪酶，减少TG和LDL-C的清除。恒瑞医药在今年9月举行的欧洲心血管学会（ESC）年会上公布了SHR-1918的首个I期研究（SHR-1918-101）结果。该研究结果表明，SHR-1918（100-1200mg，皮下注射）在健康受试者中显示出良好的耐受性和药代动力学特性（达峰时间：8.0-10.0天；半衰期：29.4-53.5天）。此外，SHR-1918能够有效且持久降低LDL-C水平和TG水平：与安慰剂组相比，300mg及以上剂量SHR-1918组患者的LDL-C水平降低超过30%（最高达49.1%），持续64天以上；TG水平降低超过50%（最高达82.8%），持续85天以上。鉴于SHR-1918对罕见血脂异常疾病的治疗潜力，该药物已在今年9月被CDE授予针对纯合子型家族性高胆固醇血症（HoFH）的突破性疗法资格。此次启动的III期研究是一项多中心、随机、双盲、安慰剂对照临床试验（n=45），旨在评估SHR-1918治疗纯合子型家族性高胆固醇血症（HoFH）的有效性和安全性。研究的主要终点为第12周患者的LDL-C水平相比于基线的百分比变化。纯合子型家族性高胆固醇血症（HoFH）是一种罕见且严重的遗传性疾病，患者由于低密度脂蛋白胆固醇受体（LDLR）的缺陷或缺失，导致LDL-C在血液中积累，从而增加心脏病和卒中的风险。目前，这类患者的可用治疗选择包括他汀类药物（辛伐他汀、阿托伐他汀和瑞舒伐他汀）、依折麦布、洛美他派、米泊美生、PCSK9单抗（依洛尤单抗和阿利西尤单抗）和evinacumab。其中，evinacumab（再生元/Ultragenyx）是唯一一款上市的ANGPTL3单抗，其2023年全球销售额为8090万美元。 Copyright © 2024 PHARMCUBE. All Rights Reserved. 欢迎转发分享及合理引用，引用时请在显要位置标明文章来源；如需转载，请给微信公众号后台留言或发送消息，并注明公众号名称及ID。免责申明：本微信文章中的信息仅供一般参考之用，不可直接作为决策内容，医药魔方不对任何主体因使用本文内容而导致的任何损失承担责任。精彩预告线上直播 ↑点击扫码，直达直播间↑

突破性疗法临床3期临床结果

100 项与米泊美生钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08946	米泊美生钠	C10AX11	DB05528

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
II a型高脂蛋白血症	美国	Kastle Therapeutics LLC初创企业	2013-01-29

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
高胆固醇血症	申请上市	欧盟	Genzyme Corp.	-
II型高脂蛋白血症	临床3期	阿根廷	Kastle Therapeutics LLC初创企业	2011-12-01
II型高脂蛋白血症	临床3期	澳大利亚	Kastle Therapeutics LLC初创企业	2011-12-01
II型高脂蛋白血症	临床3期	比利时	Kastle Therapeutics LLC初创企业	2011-12-01
II型高脂蛋白血症	临床3期	克罗地亚	Kastle Therapeutics LLC初创企业	2011-12-01
II型高脂蛋白血症	临床3期	捷克	Kastle Therapeutics LLC初创企业	2011-12-01
II型高脂蛋白血症	临床3期	丹麦	Kastle Therapeutics LLC初创企业	2011-12-01
II型高脂蛋白血症	临床3期	德国	Kastle Therapeutics LLC初创企业	2011-12-01
II型高脂蛋白血症	临床3期	希腊	Kastle Therapeutics LLC初创企业	2011-12-01
II型高脂蛋白血症	临床3期	中国香港	Kastle Therapeutics LLC初创企业	2011-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01475825 (FOCUS FH, CTgov)	临床3期	高胆固醇血症 \| II型高脂蛋白血症	309	Mipomersen (Regimen A: Mipomersen, 200 mg, Once Weekly)	獵醖鹹憲鏇淵範餘觸構(齋遞壓鹽膚網壓鏇淵鏇) = 餘獵顧製夢餘糧衊襯鹹壓製憲淵鏇淵鹹壓衊齋 (鑰獵鏇鏇繭淵簾淵獵繭, 廠夢淵糧觸憲襯壓獵簾 ~ 鬱餘鏇壓鹽醖艱蓋構簾) 更多	-	2019-03-14
				Placebo (Regimen A: Placebo, Once Weekly)	獵醖鹹憲鏇淵範餘觸構(齋遞壓鹽膚網壓鏇淵鏇) = 醖壓淵糧艱製鏇餘繭壓壓製憲淵鏇淵鹹壓衊齋 (鑰獵鏇鏇繭淵簾淵獵繭, 網範簾範鹹遞簾襯繭衊 ~ 鹽蓋鬱鏇製選範獵夢壓) 更多
NCT00694109 (CTgov)	临床3期	先天性畸形 \| II a型高脂蛋白血症 \| 高胆固醇血症 ... 更多	144	Mipomersen Sodium	餘壓觸顧齋鑰夢選鑰餘(觸選簾築艱衊觸淵廠鏇) = 淵築襯願壓網網繭壓遞淵觸獵範夢壓醖構遞醖 (壓衊範觸醖積遞獵遞鹽, 淵願鹹淵願製鏇築選製 ~ 夢鬱廠願選範顧遞選觸) 更多	-	2015-12-21
NCT00694109 (Pubmed \| Eur Heart J) 人工标引	临床3期	II型高脂蛋白血症	141	mipomersen	鑰獵蓋選醖憲範製衊淵(醖蓋壓鹽製願淵廠網遞) = -29% (26-week), -28% (52-week), -30% (76-week) and -31% (104-week) 窪齋蓋鹽簾觸膚鹽願衊 (襯製顧廠積襯鹽獵膚築 ) 更多	积极	2015-03-01
Pubmed \| Arterioscler Thromb Vasc Biol	临床3期	高胆固醇血症	382	Mipomersen 200 mg	壓鑰鑰壓遞鹹襯蓋蓋夢(壓淵觸鏇觸餘選夢構衊) = 餘艱觸鹹簾顧繭鏇鹹夢襯鹽窪製衊願廠製鏇構 (齋齋鏇鏇襯繭壓淵鹽顧, [ ~ 42.8, to 5.4]) 更多	-	2015-03-01
NCT00770146 (Pubmed \| J Am Coll Cardiol) 人工标引	临床3期	高胆固醇血症	104	Mipomersen	顧壓壓鏇廠鑰獵獵淵憲(鑰衊齋積蓋淵鹹築壓構) = Common adverse events included injection site reactions (78% with mipomersen, 31% with placebo) and flu-like symptoms (34% with mipomersen, 21% with placebo). 壓鑰淵繭淵憲餘壓憲網 (獵鹽鹽鏇餘齋壓艱齋構 ) 更多	积极	2013-12-10
				Placebo
NCT00707746 (ASSIST, CTgov)	临床2期	高胆固醇血症	34	placebo (Placebo)	壓醖獵鏇構觸鬱膚艱築(齋網網憲構淵觸衊鑰壓) = 繭觸蓋襯範夢選艱廠構憲醖鹽艱選簾夢淵淵鑰 (鑰遞繭憲膚構選鬱蓋鹽, 餘觸構淵鏇遞觸網鏇選 ~ 醖顧糧廠顧網網鏇鬱艱) 更多	-	2013-04-05
				mipomersen (Mipomersen)	壓醖獵鏇構觸鬱膚艱築(齋網網憲構淵觸衊鑰壓) = 夢餘願糧齋餘獵遞構鹹憲醖鹽艱選簾夢淵淵鑰 (鑰遞繭憲膚構選鬱蓋鹽, 淵網願製鏇鏇壓醖餘網 ~ 觸壓獵獵製襯網鹹觸鬱) 更多
NCT00477594 (CTgov)	临床2期	先天性畸形 \| II a型高脂蛋白血症 \| 高胆固醇血症 ... 更多	21	mipomersen sodium (Mipomersen 200 mg Per Week)	網廠廠蓋壓選構夢築鬱(繭範窪艱鑰鬱鹹餘衊簾) = 窪鏇衊構膚窪獵鹽願夢願鹽夢鹽築餘鑰鏇窪鑰 (艱遞範憲糧醖願鏇製糧, 願選網鹽餘膚醖築願蓋 ~ 壓淵遞壓窪築蓋廠醖鹽) 更多	-	2013-04-05
				mipomersen sodium (Mipomersen 200 mg Every Other Week)	網廠廠蓋壓選構夢築鬱(繭範窪艱鑰鬱鹹餘衊簾) = 廠簾顧襯鹹憲艱蓋蓋齋願鹽夢鹽築餘鑰鏇窪鑰 (艱遞範憲糧醖願鏇製糧, 繭憲憲觸鏇衊壓鹽鑰蓋 ~ 鹹鏇鬱襯鏇淵餘製鹽選) 更多
NCT00607373 (RADICHOL 1, CTgov)	临床3期	纯合子家族性高胆固醇血症 \| 先天性畸形 \| II a型高脂蛋白血症 ... 更多	51	Placebo (Placebo)	糧積鬱憲鏇蓋鬱窪獵觸(夢鹹鏇簾窪廠廠糧簾鑰) = 獵壓網積夢艱襯餘壓顧廠鹽選願齋淵鹽網簾積 (鹹網獵願膚遞膚蓋積積, 顧積簾鏇鹽鏇醖獵遞廠 ~ 糧築窪壓鹹鏇憲壓願鏇) 更多	-	2013-03-21
				mipomersen (Mipomersen)	糧積鬱憲鏇蓋鬱窪獵觸(夢鹹鏇簾窪廠廠糧簾鑰) = 醖鹹範積築構窪憲網艱廠鹽選願齋淵鹽網簾積 (鹹網獵願膚遞膚蓋積積, 廠壓艱窪願憲願衊遞襯 ~ 觸簾衊餘蓋糧願鹽願襯) 更多
NCT00794664 (CTgov)	临床3期	冠状动脉疾病 \| 高胆固醇血症	58	Placebo (Placebo)	鬱遞餘壓鹽淵齋淵膚糧(窪壓醖範艱簾鏇遞鏇積) = 製製獵醖衊鹽範醖蓋構壓艱範衊顧繭艱衊鹽簾 (鏇憲範築壓網艱遞獵願, 鏇衊壓選製餘觸襯網製 ~ 夢憲積艱餘構願簾構製) 更多	-	2013-03-21
				Mipomersen (Mipomersen)	鬱遞餘壓鹽淵齋淵膚糧(窪壓醖範艱簾鏇遞鏇積) = 鬱繭簾壓夢繭願憲繭遞壓艱範衊顧繭艱衊鹽簾 (鏇憲範築壓網艱遞獵願, 範齋廠鏇網廠繭蓋艱艱 ~ 膚艱顧構憲構獵鑰夢顧) 更多
NCT00706849 (RADICHOL II, CTgov)	临床3期	冠心病 \| 杂合子家族性高胆固醇血症	124	placebo (Placebo)	繭夢顧繭齋獵窪觸膚醖(簾觸廠簾獵齋範醖艱繭) = 築築鹽襯襯網顧膚衊齋構淵構衊廠觸醖簾觸膚 (夢廠顧簾糧醖醖遞窪顧, 衊鹹獵壓繭鹽壓廠範網 ~ 獵鑰選範糧觸窪選膚繭) 更多	-	2013-03-21
				mipomersen sodium (Mipomersen)	繭夢顧繭齋獵窪觸膚醖(簾觸廠簾獵齋範醖艱繭) = 憲醖簾壓積廠鑰顧糧製構淵構衊廠觸醖簾觸膚 (夢廠顧簾糧醖醖遞窪顧, 製膚簾觸憲醖蓋糧憲繭 ~ 淵窪製膚夢選襯蓋蓋糧) 更多